Journal Article Review Epublish
PubMed: 40343307 DOI: 10.1039/d5ra01427a
Protein-based nanoparticles for antimicrobial and cancer therapy: implications for public health.
RSC Adv 15(19):14966-15016
Authors: Ikhazuagbe Hilary Ifijen, Raymond Femi Awoyemi, Emmanuel Faderin, Uchenna Uzoma Akobundu, Abiola Samuel Ajayi, Janefrances U Chukwu, Ogunnaike Korede Lekan, Olutoyin Deborah Asiriuwa, Muniratu Maliki, Esther Uwidia Ikhuoria
Affiliations
- Department of Research Outreach, Rubber Research Institute of Nigeria Iyanomo, PMB 1049 Benin City Nigeria.
- Department of Chemistry, Mississippi State University Starkville Mississippi MS 39762 United State of America.
- Department of Pharmaceutical Sciences, Southern Illinois University, Edwardsville 1 Hairpin Drive Edwardsville IL 62026-001 USA.
- University of Tennessee 1000 Volunteer BLVD Knoxville TN 37916 USA.
- Texas Southern University 3100 Cleburne St Houston TX 77004 USA.
- Department of Chemistry, West Virginia University Morgantown WV 26506 USA.
- Department of Chemistry, Wichita State University 1845 Fairmount, Box 150 Wichita KS 67260-0150 USA.
- Department of Industrial Chemistry, Edo State University Iyamho Edo State Nigeria.
- Department of Chemistry, University of Benin Benin City Edo State Nigeria.
Abstract
This review discusses the growing potential of protein-based nanoparticles (PBNPs) in antimicrobial and cancer therapies, emphasizing their mechanisms of action, applications, and future prospects. In antimicrobial therapy, PBNPs exhibit several mechanisms of action, including disruption of microbial membranes, enhanced antibiotic delivery, immune modulation, and biofilm disruption. Protein nanoparticles like albumin, lactoferrin, gelatin, and peptide-based variants enhance the efficacy of antibiotics, offering targeted approaches to combat multidrug-resistant pathogens. Their ability to improve drug localization and enhance microbial eradication represents a significant advancement in infectious disease management. In cancer therapy, PBNPs facilitate targeted drug delivery, controlled release, tumor microenvironment modulation, and photothermal and photodynamic therapies. Nanoparticles such as Abraxane® and engineered ferritin nanocages are at the forefront of cancer treatment, enhancing the precision and effectiveness of chemotherapy while minimizing adverse effects. Additionally, silk fibroin nanoparticles are being explored for their biodegradability and targeting capabilities. Despite their promise, challenges remain, including the scalability of production, long-term safety concerns, regulatory approval processes, and environmental impact. Addressing these issues through rigorous research and innovation is crucial for integrating PBNPs into mainstream therapeutic practices. PBNPs offer transformative solutions in both antimicrobial and cancer therapies, with significant implications for improving public health outcomes globally.
MeSH
Nanoparticles, Pharmaceutical Preparations, Neoplasms, Fibroins, Public Health, Therapeutics